Ignite Creation Date:
2024-10-26 @ 3:41 PM
Last Modification Date:
2024-10-26 @ 3:41 PM
Study NCT ID:
NCT06613269
Status:
RECRUITING
Last Update Posted:
None
First Post:
2024-09-23
Brief Title:
68Ga-NY104 PETCT Guided Radiation Therapy in CcRCC
Sponsor:
None
Organization:
None
Study Overview
Official Title:
Effect of 68Ga-NY104 and 18F-FDG PETCT Guided Radiation Therapy Combined with Systemic Treatment in Patients with Clear Cell Renal Cell Carcinoma
Status:
RECRUITING
Status Verified Date:
2024-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
NYCRRT
Brief Summary:
Radiation therapy RT is an effective treatment for patients with advanced-stage clear cell renal cell carcinoma ccRCC Current evidence has shown promising outcomes combining radiation therapy and standard systemic therapy in patients with metastaticrecurrent ccRCC CAIX is a highly sensitive and specific biomarker expressed on ccRCC and in previous studies the investigators have shown excellent diagnostic efficacy of 68Ga-NY104 a CAIX-targeted PET tracer in patients with metastatic ccRCC In this study the investigators aim to investigate the effect of 68Ga-NY104 and 18F-FDG PETCT guided RT combining standard systemic therapy in patients with metastatic ccRCC
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None